Eli Lilly (LLY): GLP-1 Dominance, AI Drug Discovery Eli Lilly (LLYUSDT) has become the worlds most valuable pharmaceutical company, with a market capitalization near $1 trillion driven primarily by its obesity and diabetes portfolio
Typically, trials are designed to detect the most serious or common adverse effects
In the case of semaglutide, the FDA has identified the following indications for semaglutide use, breaking them down by brand: Managing blood glucose levels in adults with type 2 diabetes (Rybelsus and Ozempic) Reducing the risk of heart attack and other cardiovascular events in patients with or without diabetes and diagnosed heart disease (Ozempic) Assisting with weight loss for people classified as overweight or obese (Wegovy) Assisting weight loss for those classified as overweight and experiencing high blood pressure, type II diabetes, or dyslipidemia (Wegovy) Importantly, the majority of these approved uses come with a footnote that is oh-so-easy to gloss over: as an adjunct to diet and exercise
For this reason, we typically recommend a short series of injections, often beginning with a package of three treatments or more, depending on the therapy and your individual health goals
Neuroinflammation, vascular dysfunction, and cellular dysfunction regarding astrocytes and neurons have been discussed as underlying mechanisms contributing to these structural and functional alterations [94]
